Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03819153 · ClinicalTrials.gov registry record · Phase 3
A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease
A Phase 3 study of Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,533
- Enrollment target
- 20
- Study locations
NCT03819153 is a Phase 3 study of Diabetes Mellitus, Type 2 that has completed, run by Novo Nordisk A/S. The registered enrollment target is 3,533 participants, below the 4,475-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (21% lower). The trial reports 20 study locations across 2 states.
The verdict
NCT03819153, a Phase 3 study of Diabetes Mellitus, Type 2, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,533 participants
- Enrollment target
- 20
- Study locations
Study Summary
The researchers are doing this study to see if semaglutide can slow down the growth and worsening of chronic kidney disease in people with type 2 diabetes. Participants will get semaglutide (active medicine) or placebo ('dummy medicine'). This is known as participants' study medicine - which treatment participants get is decided by chance. Semaglutide is a medicine, doctors can prescribe in some countries for the treatment of type 2 diabetes. Participants will get the study medicine in a pen. Participants will use the pen to inject the medicine in a skin fold once a week. The study will close when there is enough information collected to show clear result of the study. The total time participants will be in this study is about 3 to 5 years, but it could be longer.
Conditions Studied
Interventions
- DRUG Semaglutide
- DRUG Placebo (semaglutide)
Study Locations (20)
California
- California Inst Of Renal Res - Chula Vista
- John Muir Physician Network - Concord
- John Muir Physicians Network - Concord
- Valley Research - Fresno
- California Institute of Renal Research - La Mesa
- First Valley Med Grp Lancaster - Lancaster
- Clinical Trials Research_Sacramento - Lincoln
- VA Loma Linda Hlthcr Sys - Loma Linda
- Long Beach Center For Clinical Research - Long Beach
- VA Long Beach Healthcare System - Long Beach
- Academic Medical Research Institute - Los Angeles
- Valley Renal Medical Group Research - Northridge
- Desert Oasis Hlthcr Med Group - Palm Springs
- Saviers Medical Group - Port Hueneme
- Inland Empire Clin Trials LLC - Rialto
- Sierra Clinical Research - Roseville
- California Research Foundation - San Diego
- N America Res Inst - San Dimas - San Dimas
- NorCal Endocrinology and Internal Medicine - San Ramon
Alabama
- Dr. Terence Hart - Tuscumbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,533 participants |
| Start Date | 2019-06-17 |
| Est. Completion | 2024-01-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03819153
The ClinicalTrials.gov registry entry for NCT03819153 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,533 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,475-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (21% lower). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Semaglutide is the first listed.
NCT03819153 reports 20 study locations spanning 2 distinct geographic areas - top geographies include California, Alabama.
Frequently Asked Questions
What is clinical trial NCT03819153 about?
NCT03819153 is a clinical study titled "A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease". The researchers are doing this study to see if semaglutide can slow down the growth and worsening of chronic kidney disease in people with type 2 diabetes. Participants will get semaglutide (active medicine) or placebo ('dummy medicine'). This is known as participants' study medicine - which treatme...
What is the current status of trial NCT03819153?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,533 participants. The study started on 2019-06-17. Estimated completion is 2024-01-09.
What conditions does trial NCT03819153 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT03819153?
The interventions under investigation include: Semaglutide (DRUG), Placebo (semaglutide) (DRUG).
Who is sponsoring clinical trial NCT03819153?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03819153 being conducted?
This trial has 20 study locations across Alabama, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.